A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 61,783 shares of CRSP stock, worth $2.92 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
61,783
Previous 57,431 7.58%
Holding current value
$2.92 Million
Previous $3.1 Million 6.39%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$44.62 - $62.75 $194,186 - $273,088
4,352 Added 7.58%
61,783 $2.9 Million
Q2 2024

Jul 19, 2024

BUY
$51.17 - $68.18 $582,877 - $776,638
11,391 Added 24.74%
57,431 $3.1 Million
Q1 2024

Apr 22, 2024

BUY
$60.67 - $89.12 $401,817 - $590,241
6,623 Added 16.8%
46,040 $3.14 Million
Q4 2023

Jan 16, 2024

BUY
$38.62 - $72.18 $233,226 - $435,895
6,039 Added 18.09%
39,417 $2.47 Million
Q3 2023

Oct 24, 2023

BUY
$45.39 - $59.0 $269,979 - $350,932
5,948 Added 21.68%
33,378 $1.52 Million
Q2 2023

Jul 25, 2023

SELL
$43.47 - $67.77 $84,201 - $131,270
-1,937 Reduced 6.6%
27,430 $1.54 Million
Q1 2023

Apr 14, 2023

BUY
$41.0 - $56.12 $86,182 - $117,964
2,102 Added 7.71%
29,367 $1.33 Million
Q4 2022

Feb 08, 2023

BUY
$39.19 - $65.67 $38,602 - $64,684
985 Added 3.75%
27,265 $1.11 Million
Q3 2022

Oct 25, 2022

BUY
$61.1 - $83.78 $335,927 - $460,622
5,498 Added 26.46%
26,280 $1.72 Million
Q2 2022

Aug 12, 2022

SELL
$43.23 - $73.83 $154,244 - $263,425
-3,568 Reduced 14.65%
20,782 $1.26 Million
Q1 2022

May 11, 2022

SELL
$53.19 - $79.24 $698,916 - $1.04 Million
-13,140 Reduced 35.05%
24,350 $1.53 Million
Q4 2021

Feb 08, 2022

BUY
$70.09 - $111.29 $561,981 - $892,323
8,018 Added 27.21%
37,490 $2.84 Million
Q3 2021

Nov 02, 2021

BUY
$110.2 - $156.64 $1.05 Million - $1.5 Million
9,564 Added 48.04%
29,472 $3.3 Million
Q2 2021

Aug 11, 2021

SELL
$100.84 - $161.89 $789,980 - $1.27 Million
-7,834 Reduced 28.24%
19,908 $3.22 Million
Q1 2021

May 14, 2021

BUY
$110.72 - $210.04 $669,191 - $1.27 Million
6,044 Added 27.86%
27,742 $3.38 Million
Q4 2020

Feb 12, 2021

BUY
$79.67 - $173.23 $512,357 - $1.11 Million
6,431 Added 42.12%
21,698 $3.32 Million
Q3 2020

Nov 04, 2020

BUY
$78.5 - $100.64 $200,960 - $257,638
2,560 Added 20.15%
15,267 $1.28 Million
Q2 2020

Jul 17, 2020

BUY
$38.5 - $76.05 $72,495 - $143,202
1,883 Added 17.4%
12,707 $934,000
Q1 2020

Apr 21, 2020

BUY
$33.68 - $62.53 $1,246 - $2,313
37 Added 0.34%
10,824 $459,000
Q4 2019

Feb 12, 2020

BUY
$36.68 - $73.13 $61,365 - $122,346
1,673 Added 18.36%
10,787 $657,000
Q3 2019

Nov 07, 2019

BUY
$40.99 - $52.56 $25,044 - $32,114
611 Added 7.19%
9,114 $374,000
Q2 2019

Aug 06, 2019

BUY
$35.45 - $48.2 $39,065 - $53,116
1,102 Added 14.89%
8,503 $400,000
Q1 2019

May 06, 2019

SELL
$28.02 - $40.87 $3,082 - $4,495
-110 Reduced 1.46%
7,401 $264,000
Q4 2018

Feb 11, 2019

SELL
$22.73 - $42.34 $125,083 - $232,997
-5,503 Reduced 42.29%
7,511 $215,000
Q2 2018

Jul 30, 2018

BUY
$42.62 - $73.59 $554,656 - $957,700
13,014 New
13,014 $765,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.69B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.